Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Psoriasis: HELP
Articles by Vinod Chandran
Based on 139 articles published since 2010
(Why 139 articles?)
||||

Between 2010 and 2020, V. Chandran wrote the following 139 articles about Psoriasis.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6
126 Article Current controversies in spondyloarthritis: SPARTAN. 2010

Weisman, Michael / Learch, Thomas J / Baraliakos, Xenofon / Chandran, Vinod / Gladman, Dafna D / Raychaudhuri, Siba P / Xu, Huji / Collantes-Estévez, Eduardo / Vázquez-Mellado, Janitzia / Mease, Philip J / Sieper, Joachim / Deodhar, Atul A / Colbert, Robert A / Clegg, Daniel O / Anonymous3800680. ·Cedars-Sinai Medical Center, Los Angeles, California, USA. ·J Rheumatol · Pubmed #21123334.

ABSTRACT: The Spondyloarthritis Research and Therapy Network (SPARTAN), founded in 2003 to promote research, education, and treatment of ankylosing spondylitis (AS) and related forms of spondyloarthritis (SpA), held its 7th Annual Research and Education Meeting in July 2009 in Houston, Texas. Current controversies in SpA discussed during the meeting included an update on the epidemiology of AS, axial SpA, and inflammatory back pain; the adequacy of the mSASS to assess radiographic involvement; the helpfulness of magnetic resonance imaging in assessing disease progression; the reliability of metrology in assessing damage; and whether biologic agents alter the course of AS. Presentations also were made on psoriasis in the SCID mouse model; the challenges and opportunities of SpA in China; a discussion of the special needs in managing SpA in Ibero-America, and the SPARK Survey in Europe and North America.

127 Article Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? 2010

Eder, Lihi / Chandran, Vinod / Shen, Hua / Cook, Richard J / Gladman, Dafna D. ·Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto Psoriatic Arthritis Clinic, Toronto Western Hospital, Toronto, Ontario, Canada. ·Ann Rheum Dis · Pubmed #20627946.

ABSTRACT: OBJECTIVE: To assess the discriminative ability and correlation of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and Bath Ankylosing Spondylitis Activity Disease Activity Index (BASDAI) with disease activity in axial psoriatic arthritis (AxPsA). METHODS: Patients with AxPsA were selected from a large prospective cohort study of psoriatic arthritis. Patient and physician global scores were used as constructs of disease activity. Patients were categorised into high and low disease activity states based on patient and physician global assessment scores and physician's decision to change treatment. Statistical analysis included descriptive statistics, linear and logistic regression. RESULTS: 201 patients with AxPsA were included in the study. ASDAS and BASDAI showed good correlation with disease activity as reflected by the patient global score (correlation coefficients (r) for BASDAI 0.84, ASDAS-B 0.77, ASDAS-C 0.81, p < 0.001) and the physician global score (r = 0.53 for BASDAI, r = 0.50 for ASDAS-B, r = 0.55 for ASDAS-C, p < 0.001). Both scores showed good discriminative ability between high and low disease activity states. However, there were no significant differences between areas under the curve for the models that compared ASDAS with BASDAI for each definition of disease activity state. CONCLUSIONS: In patients with AxPsA, ASDAS and BASDAI scores show similar good to moderate discriminative ability and correlation with different constructs of disease activity. ASDAS was not superior to BASDAI in its ability to discriminate between high and low disease activity states in AxPsA.

128 Article Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. 2010

Chandran, Vinod / Siannis, Fotios / Rahman, Proton / Pellett, Fawnda J / Farewell, Vernon T / Gladman, Dafna D. ·University of Toronto,Toronto, Canada. ·J Rheumatol · Pubmed #20472929.

ABSTRACT: OBJECTIVE: To determine the association between folate pathway gene polymorphisms and the effectiveness, toxicity, and drug survival of methotrexate (MTX) in psoriatic arthritis (PsA). METHODS: Data were obtained from a longitudinal cohort of PsA patients evaluated according to a standard protocol. Data on duration of drug therapy, dose, side effects, and reasons for discontinuation are systematically recorded. Patients treated with MTX after clinic admission who had > or = 3 swollen joints prior to initiating MTX therapy were selected for evaluation of effectiveness. Response to MTX treatment was assessed at 6 months. Data from all patients treated in the clinic with MTX were used in evaluation of toxicity and drug survival. The following single-nucleotide polymorphisms (SNP) were measured using the Sequenom platform: MTHFR 677C>T (rs1801133), MTHFR 1298A>C (rs1801131), DHFR -473T>C (rs1650697), DHFR 35289A>G (rs1232027), and RFC 80G>A (rs1051266). Fisher's exact test, logistic regression, and Cox proportional hazard analyses were used to determine association. RESULTS: Two hundred eighty-one patients were identified from the database. All patients were included in the analysis for side effects and drug survival, and 119 patients were included in the effectiveness analysis. The minor A allele of DHFR gene at +35289 was the only SNP demonstrating association with response to MTX therapy (OR 2.99, p = 0.02). Patients homozygous for the minor allele of MTHFR 677C/T (677TT) had more liver toxicity (Fisher exact test, p = 0.04). CONCLUSION: Polymorphisms of the DHFR gene may be associated with MTX efficacy. MTHFR 677TT may have a relationship with MTX-induced liver toxicity in PsA.

129 Article Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. 2010

Chandran, Vinod / Cook, Richard J / Edwin, Jonathan / Shen, Hua / Pellett, Fawnda J / Shanmugarajah, Sutharshini / Rosen, Cheryl F / Gladman, Dafna D. ·Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada. ·Rheumatology (Oxford) · Pubmed #20421218.

ABSTRACT: OBJECTIVE: Biomarkers may be helpful in screening patients with psoriasis for PsA. Our purpose was to identify serum biomarkers for psoriasis and PsA. METHODS: Fifty-two patients with psoriasis (26 satisfying CASPAR classification criteria for PsA) and 26 healthy controls were recruited for our study. Patients with psoriasis and PsA were group matched for age, sex and psoriasis duration, whereas controls were matched for age and sex. Blood samples were drawn at the time of assessment and serum was analysed for the following: IL-12, IL-12p40, IL-17, TNF super family member 14 (TNFSF14), MMP-3, RANK ligand (RANKL), osteoprotegerin (OPG), cartilage oligomeric matrix protein (COMP), C-propeptide of Type II collagen (CPII), collagen fragment neoepitopes Col2-3/4(long mono) (C2C) and Col2-3/4(short) (C1-2C) and highly sensitive CRP (hsCRP). Data were analysed using logistic regression and receiver operating characteristic curves were plotted. RESULTS: Fifty-two patients with psoriatic disease had a mean age of 46 years and psoriasis duration of 16.8 years. Compared with controls, increased serum levels of RANKL, TNFSF14, MMP-3 and COMP independently associated with psoriatic disease (P < 0.05). Twenty-six PsA patients (mean swollen and/or tender joint count 16, swollen joint count 5) were then compared with 26 patients who had psoriasis alone. Increased levels of hsCRP, OPG, MMP-3 and the CPII : C2C ratio were independently associated with PsA (P < 0.03). CONCLUSION: This pilot study indicates that hsCRP, OPG, MMP-3 and the CPII : C2C ratio are biomarkers for PsA in patients with psoriasis.

130 Article Predictors of response to intra-articular steroid injection in psoriatic arthritis. 2010

Eder, Lihi / Chandran, Vinod / Ueng, Joanna / Bhella, Sita / Lee, Ker-Ai / Rahman, Proton / Pope, Angela / Cook, Richard J / Gladman, Dafna D. ·Psoriatic Arthritis Program, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada. ·Rheumatology (Oxford) · Pubmed #20388640.

ABSTRACT: OBJECTIVES: To assess the effectiveness of IA corticosteroid (IAS) injections in PsA and to determine the association between macrophage migration inhibition factor (MIF) gene polymorphism and response to IAS injections. METHODS: A cohort analysis of PsA patients who were followed prospectively was performed. Clinical response was defined as no tenderness or effusion in the injected joint at 3 months. Relapse was defined as re-occurrence of joint pain or effusion. MIF 173C > G genotyping (rs755622) was performed. RESULTS: Two hundred and twenty patients with 245 IAS injections were included in the study. The probability of responding at 3 months was 41.6%. Within 12 months, 25.5% of the joints relapsed. Clinical factors that were associated with response included duration of psoriasis [Odds ratio (OR) 1.03] and the use of MTX or anti-TNF agents at the time of injection (OR 2.68). Factors that were associated with relapse included injection into large joints (OR 4.58) and elevated sedimentation rate (OR 15.0), whereas absence of clinical and/or radiographic damage (OR 0.23) and duration of PsA (OR 0.92) reduced risk of relapse. MIF polymorphism was not associated with clinical response, but was associated with relapse (OR 3.2). On multivariate analysis including clinical covariates, the association between MIF polymorphism and relapse was lost. CONCLUSIONS: IAS injections are effective in PsA. MIF gene polymorphism is associated with relapse. However, this effect is explained by clinical variables that reflect disease activity, suggesting that MIF gene polymorphism influences inflammatory activity.

131 Article Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. 2010

Eder, Lihi / Chandran, Vinod / Schentag, Catherine T / Shen, Hua / Cook, Richard J / Gladman, Dafna D. ·Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, ON, Canada. ·Rheumatology (Oxford) · Pubmed #20385615.

ABSTRACT: OBJECTIVE: To determine predictors and time to response to treatment with TNF-alpha blockers in patients with PsA in a longitudinal observational cohort. METHODS: We performed a cohort analysis of patients who were followed prospectively in a large PsA clinic. Response to treatment was defined as an improvement of at least 40% in active (tender and/or swollen) and swollen joint count (SJC) and 50% improvement in the Psoriasis Area and Severity Index (PASI) score. RESULTS: Ninety-five patients were included in the analysis. Of the total patients, 72.6 and 77.9% demonstrated 40% improvement in active joint counts at 3 and 12 months, respectively. Also, 80.5 and 87.4% of the patients showed 40% improvement in SJC at 3 and 12 months, respectively. A PASI50 was achieved by 54 and 60.4% after 3 and 12 months of treatment, respectively. Of 17 patients who did not achieve 40% improvement in total SJC at 3 months, 11 (64.7%) responded at 12 months. In multivariate analysis, the number of swollen joints at baseline predicted response of total active joints at 12 months [odds ratio (OR) 1.34; P = 0.02], whereas past use of TNF-alpha blocker decreased odds of response (OR 0.05; P = 0.01). CONCLUSION: TNF-alpha blockers are effective in most PsA patients with the majority responding within 3 months of treatment. A significant proportion of the early non-responders will have a delayed response to treatment. Higher SJC at baseline and no prior use of TNF-alpha blockers predict response.

132 Article Risk factors for axial inflammatory arthritis in patients with psoriatic arthritis. 2010

Chandran, Vinod / Tolusso, David C / Cook, Richard J / Gladman, Dafna D. ·Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Ontario, Canada. ·J Rheumatol · Pubmed #20231209.

ABSTRACT: OBJECTIVE: Axial involvement is an important manifestation of psoriatic arthritis (PsA). We aimed to identify risk factors associated with the presence of axial PsA (AxPsA) in patients with PsA. METHODS: Patients with AxPsA (bilateral sacroiliitis >or= grade 2/unilateral sacroiliitis >or= 3 and inflammatory neck/back pain or limited spinal mobility) at first clinic visit were identified from the University of Toronto PsA clinic database. Risk factors associated with the presence of AxPsA were determined. Subsequently, patients without AxPsA at first clinic visit were identified. Under a multistate framework, the proportion of patients with PsA who subsequently developed AxPsA was estimated robustly using marginal methods and a Markov model. Risk factors at baseline that were associated with future development of AxPsA were identified through multiplicative time-homogeneous Markov models. RESULTS: Our study included 206 patients. Fifty patients had AxPsA at first clinic visit. HLA-B*27, radiographic damage to peripheral joints, and elevated erythrocyte sedimentation rate (ESR) increased odds of having AxPsA, while family history of PsA decreased the odds. One hundred fifty-six patients did not have AxPsA at first clinic visit. On followup, 28 developed AxPsA, and 11 died. We estimated that after 10 years of followup, 15% would develop AxPsA. Nail dystrophy, number of radiographically damaged joints, periostitis, and elevated ESR increased the risk of developing AxPsA, while swollen joints decreased the risk. CONCLUSION: These results suggest that severe peripheral arthritis and HLA-B*27 are risk factors for AxPsA.

133 Article Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. 2010

Coates, Laura C / Cook, Richard / Lee, Ker-Ai / Chandran, Vinod / Gladman, Dafna D. ·University of Leeds, Chapel Allerton Hospital, Leeds, UK. ·Arthritis Care Res (Hoboken) · Pubmed #20191569.

ABSTRACT: OBJECTIVE: To establish the frequency and predictors of minimal disease activity in psoriatic arthritis (PsA) and to investigate the prognostic ability of minimal disease activity criteria to predict future joint damage. METHODS: The study was conducted using an observational PsA cohort. Patients were classified as being in minimal disease activity if they fulfilled the criteria on consecutive visits for >12 months. Predictive factors for minimal disease activity and joint damage were investigated using regression models. Joint damage progression was based on clinically damaged joint counts. RESULTS: Of the 344 patients, 208 (60%) achieved minimal disease activity at > or = 1 visit and 116 (34%) achieved minimal disease activity for > or = 12 months (sustained minimal disease activity). The average duration of minimal disease activity was 28 months (range 12-48 months). Twelve patients (10%) experienced a flare of disease after 34 months in minimal disease activity. Low erythrocyte sedimentation rate (ESR) and oligoarthritis were predictors of achieving sustained minimal disease activity (P < 0.03). The mean change in damaged joint counts was 0.931 (range 0-12) in the sustained minimal disease activity group and 2.245 (range 0-17) in the controls (P < 0.001). Of the sustained minimal disease activity group, 69% showed no progression of joint damage, compared with 51% in the control group. Elevated ESR, baseline joint damage, and use of biologic therapies increased the likelihood of damage progression (P < 0.05). CONCLUSION: Minimal disease activity was achieved by a significant proportion of patients and was sustained in one-third of the population studied. Patients achieving sustained minimal disease activity had a significant reduction in joint damage progression. Other factors, representing disease activity and disease severity, impact on the likelihood of achieving sustained minimal disease activity and on damage progression.

134 Minor Drs. Maharaj and Chandran reply. 2015

Maharaj, Ajesh B / Chandran, Vinod. ·Department of Clinical Immunology and Rheumatology, Academic Medical center, University of Amsterdam, Amsterdam, the Netherlands; maharaja30@ukzn.ac.za. · Department of Medicine, Division of Rheumatology, University of Toronto, and Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada. ·J Rheumatol · Pubmed #26034234.

ABSTRACT: -- No abstract --

135 Minor Pancytopenia in a patient with psoriatic arthritis treated with methotrexate and concomitant lithium. 2015

Maharaj, Ajesh B / Chandran, Vinod. ·Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, the Netherlands, and Prince Mshiyeni Memorial Hospital, Department of Internal Medicine, Nelson R. Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa; maharaja30@ukzn.ac.za. · Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada. ·J Rheumatol · Pubmed #25729049.

ABSTRACT: -- No abstract --

136 Minor Gene expression differences between psoriasis patients with and without inflammatory arthritis. 2015

Pollock, Remy A / Abji, Fatima / Liang, Kun / Chandran, Vinod / Pellett, Fawnda J / Virtanen, Carl / Gladman, Dafna D. ·Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Research Institute, University of Toronto, Toronto, Ontario, Canada. · Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada. · Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Research Institute, University of Toronto, Toronto, Ontario, Canada; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. · University Health Network Microarray Centre, Toronto, Ontario, Canada. · Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Research Institute, University of Toronto, Toronto, Ontario, Canada; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: dafna.gladman@utoronto.ca. ·J Invest Dermatol · Pubmed #25243786.

ABSTRACT: -- No abstract --

137 Minor Spondyloarthritis: CASPAR criteria in early psoriatic arthritis. 2012

Chandran, Vinod. · ·Nat Rev Rheumatol · Pubmed #22825727.

ABSTRACT: -- No abstract --

138 Unspecified Update on biomarkers in psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. 2012

Fitzgerald, Oliver / Chandran, Vinod. ·Department of Rheumatology, St Vincent’s University Hospital and Conway Institute, University College Dublin, Dublin, Ireland. oliver.fitzgerald@ucd.ie ·J Rheumatol · Pubmed #22298273.

ABSTRACT: Biomarkers may be used to screen patients with psoriasis for psoriatic arthritis (PsA) and to assess disease activity and severity. Candidate biomarkers should fulfil the key features of the OMERACT (Outcome Measures in Rheumatology) filter, that is, truth, discrimination, and feasibility. A number of biomarkers are currently being investigated in psoriatic disease for important clinical outcomes. Serum high sensitivity C-reactive protein, cartilage oligomeric matrix protein, interleukin 6 (IL-6), osteoprotegerin, matrix metalloprotease-3 (MMP-3), and the ratio of C-propeptide of type II collagen (CPII) to collagen fragment neoepitopes Col2-3/4 (long mono) (C2C) show promise as serum biomarkers that distinguish subjects with PsA from those with psoriasis alone. Serum MMP-3 and melanoma inhibitory activity, synovial fluid IL-1, IL-1 receptor-α, IL-6, IL-8, and chemokine CCL3 and synovial tissue CD3-positive T cells may prove useful as biomarkers of PsA activity. Circulating osteoclast precursors, Dickkopf-1, macrophage colony stimulating factor, receptor activator of nuclear factor-κB ligand, and bone alkaline phosphatase are strong candidates as biomarkers of radiographic change. Prospective studies to identify biomarkers for psoriatic disease are high on the research agenda of the Group for Research and Assessment of Psoriasis and PsA.

139 Minor Expression patterns of natural killer receptor genes in inflamed joints and peripheral blood of patients with psoriatic arthritis. 2011

Pollock, R A / Pellett, F J / Chandran, V / Gladman, D D. · ·Tissue Antigens · Pubmed #21883096.

ABSTRACT: -- No abstract --

Back